Michael and Regan Dube will pay a total of $9,015,046, plus interest as a result of their convictions. Regan Dube was previously sentenced in November.
The healthcare company and its subsidiary allegedly ordered residents of a residential treatment center to undergo unnecessary drug screenings multiple times a week.
UPenn researchers believe that their lateral flow assay has the potential to be the first point-of-care test that can detect fentanyl and its metabolite, norfentanyl, at clinically relevant cutoffs.
Since FDA's actions, the company has implemented a program in which customers must sign a certification letter saying they are using its products as intended.
